Hercules Capital, Inc. is a business development company. The firm specializing in providing venture debt, debt, senior secured loans, and growth capital to privately held venture capital-backed companies at all stages of development from startups, to expansion stage including select publicly listed companies and select special opportunity lower middle market companies that require additional capital to fund acquisitions, recapitalizations and refinancing and established-stage companies. The firm provides growth capital financing solutions for capital extension; management buy-out and corporate spin-out financing solutions; company, asset specific, or intellectual property acquisition financing; convertible, subordinated and/or mezzanine loans; domestic and international corporate expansion; vendor financing; revenue acceleration by sales and marketing development, and manufacturing expansion. It provides asset-based financing with a focus on cash flow; accounts receivable facilities; equipment loans or leases; equipment acquisition; facilities build-out and/or expansion; working capital revolving lines of credit; inventory. The firm also provides bridge financing to IPO or mergers and acquisitions or technology acquisition; dividend recapitalizations and other sources of investor liquidity; cash flow financing to protect against share price volatility; competitor acquisition; pre-IPO financing for extra cash on the balance sheet; public company financing to continue asset growth and production capacity; short-term bridge financing; and strategic and intellectual property acquisition financings. It also focuses on customized financing solutions, emerging growth, mid venture, and late venture financing. The firm invests primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The firm generally seeks to invest in companies that have been operating for at least six to 12 months prior to the date of their investment. It prefers to invest in technology, energy technology, sustainable and renewable technology, and life sciences. Within technology the firm focuses on advanced specialty materials and chemicals; communication and networking, consumer and business products; consumer products and services, digital media and consumer internet; electronics and computer hardware; enterprise software and services; gaming; healthcare services; information services; business services; media, content and information; mobile; resource management; security software; semiconductors; semiconductors and hardware; and software sector. Within energy technology, it invests in agriculture; clean technology; energy and renewable technology, fuels and power technology; geothermal; smart grid and energy efficiency and monitoring technologies; solar; and wind. Within life sciences, the firm invests in biopharmaceuticals; biotechnology tools; diagnostics; drug discovery, development and delivery; medical devices and equipment; surgical devices; therapeutics; pharma services; and specialty pharmaceuticals. It also invests in educational services. The firm invests primarily in United States based companies and considers investment in the West Coast, Mid-Atlantic regions, Southeast and Midwest; particularly in the areas of software, biotech and information services. It invests generally between $1 million to $40 million in companies focused primarily on business services, communications, electronics, hardware, and healthcare services. The firm invests primarily in private companies but also have investments in public companies. For equity investments, the firm seeks to represent a controlling interest in its portfolio companies which may exceed 25% of the voting securities of such companies. The firm seeks to invest a limited portion of its assets in equipment-based loans to early-stage prospective portfolio companies. These loans are generally for amounts up to $3 million but may be up to $15 million for certain energy technology venture investments. The firm allows certain debt investments have the right to convert a portion of the debt investment into equity. It also co-invests with other private equity firms. The firm seeks to exit its investments through initial public offering, a private sale of equity interest to a third party, a merger or an acquisition of the company or a purchase of the equity position by the company or one of its stockholders. The firm has structured debt with warrants which typically have maturities of between two and seven years with an average of three years; senior debt with an investment horizon of less than three years; equipment loans with an investment horizon ranging from three to four years; and equity related securities with an investment horizon ranging from three to seven years. The firm prefers to invest through its balance sheet capital. The firm formerly known as Hercules Technology Growth Capital, Inc. Hercules Capital, Inc. was founded in Decembe
IPO Year: 2012
Exchange: NYSE
Website: htgc.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/13/2026 | $17.50 | Overweight → Neutral | Piper Sandler |
| 11/4/2025 | $19.50 | Neutral → Buy | Compass Point |
| 12/12/2024 | $19.50 → $21.50 | Mkt Perform → Outperform | Keefe Bruyette |
| 1/16/2024 | $17.00 → $17.50 | Buy → Neutral | Compass Point |
| 11/21/2023 | $17.00 | Neutral | UBS |
| 8/30/2023 | $17.50 | Neutral → Buy | Compass Point |
| 8/4/2023 | $13.50 → $17.00 | Underperform → Mkt Perform | Keefe Bruyette |
| 4/6/2023 | $16.00 | Neutral → Overweight | Piper Sandler |
| 3/13/2023 | $14.50 → $10.50 | Mkt Perform → Underperform | Keefe Bruyette |
| 7/29/2022 | Outperform → Perform | Oppenheimer |
8-K - Hercules Capital, Inc. (0001280784) (Filer)
10-Q - Hercules Capital, Inc. (0001280784) (Filer)
DEFA14A - Hercules Capital, Inc. (0001280784) (Filer)
8-K - Hercules Capital, Inc. (0001280784) (Filer)
DEFA14A - Hercules Capital, Inc. (0001280784) (Filer)
DEF 14A - Hercules Capital, Inc. (0001280784) (Filer)
ABS-15G - Hercules Capital, Inc. (0001280784) (Filer)
8-K - Hercules Capital, Inc. (0001280784) (Filer)
10-K - Hercules Capital, Inc. (0001280784) (Filer)
8-K - Hercules Capital, Inc. (0001280784) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Piper Sandler downgraded Hercules Capital from Overweight to Neutral and set a new price target of $17.50
Compass Point upgraded Hercules Capital from Neutral to Buy and set a new price target of $19.50
Keefe Bruyette upgraded Hercules Capital from Mkt Perform to Outperform and set a new price target of $21.50 from $19.50 previously
Compass Point downgraded Hercules Capital from Buy to Neutral and set a new price target of $17.50 from $17.00 previously
UBS initiated coverage of Hercules Capital with a rating of Neutral and set a new price target of $17.00
Compass Point upgraded Hercules Capital from Neutral to Buy and set a new price target of $17.50
Keefe Bruyette upgraded Hercules Capital from Underperform to Mkt Perform and set a new price target of $17.00 from $13.50 previously
Piper Sandler upgraded Hercules Capital from Neutral to Overweight and set a new price target of $16.00
Keefe Bruyette downgraded Hercules Capital from Mkt Perform to Underperform and set a new price target of $10.50 from $14.50 previously
Oppenheimer downgraded Hercules Capital from Outperform to Perform
Fastest customizable press release news feed in the world
The $300m facility backed by top-tier lenders reflects strong conviction in Perk's vision to build a leading AI-native platform for travel and spend management Perk enters its next phase of growth on the back of a 48% revenue growth in 2025, best-in-category gross margins, and a platform built for global scale The new credit facility upsizes and replaces Perk's prior facility on materially improved terms, while increasing available capital to further strengthen an already strong balance sheet Perk (formerly TravelPerk), the AI-native travel and spend management platform, today announced the close of a $300 million private credit facility led by Neuberger Speciality Finance, alongs
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules," "Hercules Capital," or the "Company"), will conduct its 2026 Annual Meeting of Stockholders by virtual meeting on Thursday, June 18, 2026 at 9:00 a.m. (Eastern Time). The proxy statement for the meeting was filed on April 23, 2026 and mailed to stockholders of record as of April 9, 2026. 2026 Annual Meeting of Stockholders June 18, 2026 at 9:00 a.m. Eastern Time Virtual Meeting via Internet: http://www.virtualshareholdermeeting.com/HTGC2026 Matters to be voted on include: 1) election of an independent director, 2) an advisory vote to approve the Company's named executive officer compensation, 3) an advisory vote on the frequency of the adv
Record Q1 2026 Total New Debt and Equity Commitments of $1.81 Billion, an Increase of 77.8% Year-over-Year Q1 2026 Total Fundings of $706.4 Million, an Increase of 31.0% Year-over-Year Record Q1 2026 Total Investment Income of $141.5 Million, an Increase of 18.4% Year-over-Year Q1 2026 Net Investment Income "NII" of $88.1 Million, an Increase of 13.8% Year-over-Year Q1 2026 NII of $0.48 per Share provides 120% Coverage of the Base Cash Distribution Closed Institutional Notes Offering of $300.0 Million of 5.350% Unsecured Notes due 2029 Conservative Balance Sheet Management with Net GAAP Leverage of 113.5% and Net Regulatory Leverage of 97.8%(1) Inclusive of the Adviser Funds A
THE WOODLANDS, Texas, May 04, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced today that it has entered into a loan facility with Hercules Capital, Inc. (NYSE:HTGC) that provides up to $100 million in borrowing capacity. Access to this non-dilutive capital provides Lexicon with greater financial flexibility through both an extended interest-only period and maturity date and the opportunity to further strengthen its balance sheet to support pivotal upcoming regulatory and commercial milestones. "Operational excellence, financial discipline and financial flexibility are key pillars of our corporate strategy for long-term growth," said Scott Coiante, Lexicon's
GERMANTOWN, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to transform lives in the global diabetes community, announced that it has entered into a Second Amendment to the Loan and Security Agreement with Hercules Capital, Inc. (NYSE:HTGC). The Second Amendment increases the maximum borrowing capacity under the existing facility from $100 million to $140 million. In addition to $35 million of borrowings currently outstanding under the existing facility, the amended facility will: Provide for $20 million of near-term loan commitments
Seth Meyer Elevated to President Andrew Olson Appointed Chief Financial Officer and Head of Corporate Development Hercules Capital, Inc. (NYSE:HTGC) ("Hercules," "Hercules Capital," or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced a strategic evolution of its executive leadership team to accelerate its next phase of growth and operational scaling. Effective May 18, 2026, Seth Meyer, who has served as Chief Financial Officer since 2019, will be promoted to President. Succeeding him as Chief Financi
The Total Cash Distribution of $0.47 per Share for the First Quarter 2026 is Comprised of a $0.40 per Share Base Distribution and $0.07 per Share Supplemental Distribution Hercules Capital, Inc. (NYSE:HTGC) ("Hercules," "Hercules Capital," or the "Company"), the largest and leading specialty financing provider to innovative, venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, is pleased to announce that its Board of Directors has declared a first quarter 2026 total cash distribution of $0.47 per share. The following shows the key dates of the first quarter 2026 distribution payment: Record Date
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules," "Hercules Capital," or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its first quarter 2026 financial results conference call for Tuesday, May 5, 2026, at 2:00 p.m. PT (5:00 p.m. ET). Hercules will release its financial results after market close that same day. All interested parties are invited to participate via telephone or the live webcast, which will be hosted on a webcast link located on the Investor Resources section of our
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules," "Hercules Capital," or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced it has set a new all-time record of $1.81 billion in new debt and equity commitments for the first quarter of 2026. "Coming off a record-breaking performance for gross new debt and equity commitments and fundings in 2025, our momentum accelerated in Q1 — marked by an all-time high in new debt and equity commitments," said Scott Bluestein, chief executive officer and chief investment o
LEGEND pivotal cohort update planned for a spring 2026 medical conference 12-month complete response data from LEGEND pivotal cohort expected in 2H 2026 Biologics License Application (BLA) submission for detalimogene planned for 2H 2026 Cash and marketable securities of $312.5 million expected to provide cash runway into 2H 2028 Expanded $125 million debt facility with Hercules Capital provides additional financial flexibility to advance detalimogene development and commercialization for bladder cancer enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter en
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4/A - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4/A - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
Live finance-specific insights
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules," "Hercules Capital," or the "Company"), will conduct its 2026 Annual Meeting of Stockholders by virtual meeting on Thursday, June 18, 2026 at 9:00 a.m. (Eastern Time). The proxy statement for the meeting was filed on April 23, 2026 and mailed to stockholders of record as of April 9, 2026. 2026 Annual Meeting of Stockholders June 18, 2026 at 9:00 a.m. Eastern Time Virtual Meeting via Internet: http://www.virtualshareholdermeeting.com/HTGC2026 Matters to be voted on include: 1) election of an independent director, 2) an advisory vote to approve the Company's named executive officer compensation, 3) an advisory vote on the frequency of the adv
Record Q1 2026 Total New Debt and Equity Commitments of $1.81 Billion, an Increase of 77.8% Year-over-Year Q1 2026 Total Fundings of $706.4 Million, an Increase of 31.0% Year-over-Year Record Q1 2026 Total Investment Income of $141.5 Million, an Increase of 18.4% Year-over-Year Q1 2026 Net Investment Income "NII" of $88.1 Million, an Increase of 13.8% Year-over-Year Q1 2026 NII of $0.48 per Share provides 120% Coverage of the Base Cash Distribution Closed Institutional Notes Offering of $300.0 Million of 5.350% Unsecured Notes due 2029 Conservative Balance Sheet Management with Net GAAP Leverage of 113.5% and Net Regulatory Leverage of 97.8%(1) Inclusive of the Adviser Funds A
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules," "Hercules Capital," or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its first quarter 2026 financial results conference call for Tuesday, May 5, 2026, at 2:00 p.m. PT (5:00 p.m. ET). Hercules will release its financial results after market close that same day. All interested parties are invited to participate via telephone or the live webcast, which will be hosted on a webcast link located on the Investor Resources section of our
Record Full-Year 2025 Total New Debt and Equity Commitments of $3.92 Billion, an Increase of 45.7% Year-over-Year Record Full-Year 2025 Total Fundings of $2.28 Billion, an Increase of 25.9% Year-over-Year Record Full-Year 2025 Total Investment Income of $532.5 Million, an Increase of 7.9% Year-over-Year Record Full-Year 2025 Net Investment Income "NII" of $341.7 Million, an Increase of 4.9% Year-over-Year Record Q4 2025 Total Gross Debt and Equity Commitments of $1.06 Billion, an Increase of 70.8% Year-over-Year Q4 2025 NII of $0.48 per Share provides 120% Coverage of the Base Cash Distribution Conservative Balance Sheet Management with Net Leverage of 101.8% and Net Regulatory
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules," "Hercules Capital," or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its fourth quarter and full-year 2025 financial results conference call for Thursday, February 12, 2026, at 2:00 p.m. PT (5:00 p.m. ET). Hercules will release its financial results after market close that same day. All interested parties are invited to participate via telephone or the live webcast, which will be hosted on a webcast link located on the Investor Re
Q3 2025 Total New Debt and Equity Commitments of $846.2 Million Record Q3 2025 Total Fundings of $504.6 Million Record Year-to-Date Ending Q3 2025 Total Debt and Equity Commitments of $2.87 Billion Record Year-to-Date Ending Q3 2025 Total Fundings of $1.75 Billion Record Q3 2025 Total Investment Income of $138.1 Million Q3 2025 Net Investment Income "NII" of $88.6 Million Q3 2025 NII of $0.49 per Share provides 122% Coverage of the Base Cash Distribution Conservative Balance Sheet Management with Net GAAP Leverage of 98.2% and Net Regulatory Leverage of 82.3%(1) Inclusive of the Adviser Funds Advised by Hercules Adviser LLC, its Wholly-owned Subsidiary, Hercules had over $1.
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules," "Hercules Capital," or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its third quarter 2025 financial results conference call for Thursday, October 30, 2025, at 2:00 p.m. PT (5:00 p.m. ET). Hercules will release its financial results after market close that same day. All interested parties are invited to participate via telephone or the live webcast, which will be hosted on a webcast link located on the Investor Resources section
CGM commercial operations to transition from Ascensia Diabetes Care to Senseonics Brian Hansen to be appointed Chief Commercial Officer Non-dilutive debt facility expanded up to $100 million with Hercules Capital to fund commercial organization Conference Call scheduled for September 4, 2025 at 8:00 A.M. Eastern Time GERMANTOWN, Md., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced a mutually executed Memorandum of Understanding to transition all commercialization and distributio
CARY, N.C., Aug. 8, 2025 Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the completion of a comprehensive capital restructuring designed to enhance the Company's financial flexibility, reduce total debt, and support long-term growth. The multi-faceted refinancing transaction consisted of the following key components: A new senior credit facility with Hercules Capital, Inc. (NYSE:HTGC), due in 2030, which provides $110.0 million in committed capital at closing and an additional $40.0 million in two $20.0 million tranches available upon achievement of certain milestones, to be drawn at the Company's discretion;An exc
Q2 2025 Total Gross Debt and Equity Commitments of $1.0 Billion Record Q2 2025 Total Gross Fundings of $709.1 Million Record 1H 2025 Total Gross Debt and Equity Commitments of $2.02 Billion Record 1H 2025 Total Gross Fundings of $1.25 Billion Record Q2 2025 Net Investment Income "NII" of $88.7 Million Q2 2025 NII of $0.50 per Share provides 125% Coverage of the Base Cash Distribution Closed Upsized Offering of $350.0 Million of 6.000% Unsecured Notes due 2030 Renewed and Increased Its Credit Facility with MUFG Bank, Ltd. to $440.0 Million Conservative Balance Sheet Management with Net GAAP Leverage of 95.0% and Net Regulatory Leverage of 78.7%(1) Inclusive of the Adviser F
This live feed shows all institutional transactions in real time.
SC 13G - Hercules Capital, Inc. (0001280784) (Subject)
SC 13G/A - Hercules Capital, Inc. (0001280784) (Filed by)
SC 13G - Hercules Capital, Inc. (0001280784) (Filed by)
Live Leadership Updates
Strategic growth financing accelerates expansion through acquisition and supports product innovation Snappt, the leading platform for applicant trust in multifamily housing, today announced it has acquired Trigo, a company known for its breakthrough technology in verifying rental payment history. Backed by a $50 million committed facility from Hercules Capital, Inc. (NYSE:HTGC), the acquisition expands Snappt's platform and strengthens its ability to help property managers make faster, more confident leasing decisions. Together, these milestones mark a major step toward building the industry's most complete and trusted solution embedded into the application and screening process. "This
SAUSALITO, Calif., Nov. 29, 2023 /PRNewswire/ -- Revelation Partners, a healthcare investment firm with over $1.5 billion of capital under management, announced today the addition of Andrew Olson as Partner, Chief Financial Officer and Chief Operating Officer. Mr. Olson has an extensive background in the venture capital and funds management industry. His addition to the team will enhance the firm's technical expertise, support the differentiated investment model, and strengthen the firm's ongoing foundation. As the firm's new Chief Financial Officer and Chief Operating Officer
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Nikos Theodosopoulos was appointed to serve as an independent member of its board of directors, effective September 21, 2023. Mr. Theodosopoulos is an experienced corporate executive and board director with more than 38 years in senior management roles in both the financial services and technology industries. Mr. Theodosopoulos will serve on the Company's Audit Committee. "Nikos' combined experienc
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that DeAnne Aguirre was appointed to serve as an independent member of its board of directors, effective June 23, 2022. Ms. Aguirre is an experienced corporate executive and Board Director with more than 30 years in senior leadership managing large and complex domestic and international business units. Ms. Aguirre will serve on the Nominating and Corporate Governance Committee. "As we continue to expand o
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Pam Randhawa was appointed to serve as a member of its board of directors, effective November 1, 2021. Ms. Randhawa is a thought leader within the life sciences sector and an experienced industry executive, with more than 20 years of experience leading public and private companies, ranging from biotech, healthcare and sustainable solutions, through their various stages of growth. Ms. Randhawa will ser
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that effective July 1, 2021, Wade Loo was appointed to the Hercules board of directors. Mr. Loo brings over 40 years of business experience in all aspects of financial reporting serving public companies – from emerging startups going public to large-cap multinationals. Mr. Loo will serve on the Audit Committee. "Wade provides relevant financial business expertise that complements our leading venture lendi